CURIOUS CASE OF DRUG RESISTANT MALARIA AND ARTEMISININ COMPOUNDS IN THE MODERN ERA

  • Mudasir Maqbool Research Scholar, Department of Pharmaceutical Sciences, University of Kashmir, Hazratbal Srinagar-190006, Jammu and Kashmir, India
  • Amin Mohamad Dar Research Scholar, Department of Pharmaceutical Sciences, University of Kashmir, Hazratbal Srinagar-190006, Jammu and Kashmir, India
  • Shafiqa Rasool Research Scholar, Department of Pharmaceutical Sciences, University of Kashmir, Hazratbal Srinagar-190006, Jammu and Kashmir, India
  • Misba Khan Research Scholar, Mader-E-Meharban Institute of Nursing Sciences and Research, SKIMS, Soura, Jammu and Kashmir, India
DOI https://doi.org/10.31069/japsr.v2i2.1

Abstract

Malaria is caused by Plasmodium parasite, transmitted by the bite of infective female Anopheles mosquito. The four species causing human infections are P falciparum, P vivax, P malariae and P ovale. P falciparum causes the majority of infections and is main culprit for most severe disease and mortality. Whereas P. vivax and P. ovale form resting stages in the liver (hypnozoites), that once reactivated, can lead to a clinical relapse many months after the initial event. The effective treatment is now compounded by the spread of drug resistant strains of the parasite. As a result, traditional alkaloid drugs such as chloroquine and quinine are now largely ineffective. The spread of parasite resistance has led the World Health Organization (WHO) to predict that without new antimalarial drug intervention, the number of cases of malaria will definitely increase. The growing menace of drug resistance has greatly complicated the treatment for malaria. Whereas chloroquine and sulfadoxine/pyrimethamine could once cure most infections, this is no longer true and requires examination of alternative regimens for the treatment of malaria. Artemisinin-based combinations are now widely accepted as the best treatments for uncomplicated falciparum malaria. Such combination treatments are rapid and reliably effective. The efficacy of the treatment is determined by the drug partnering the artemisinin derivative and, for artesunate-mefloquine, artemether-lumefantrine, and dihydroartemisinin-piperaquine, this usually exceeds 95%. This paper unfolds resistance to various conventional antimalarials and brief outline about artemisinin derivatives.

Keywords: Malaria, Chloroquine, Artesunate, Artemether, Artemisnin

Downloads

Download data is not yet available.

References

1. Gaur R, Cheema HS, Kumar Y, Singh SP, Yadav DK, Darokar MP, Khan F, Bhakuni RS. In vitro antimalarial activity and molecular modeling studies of novel artemisinin derivatives. RSC Advances. 2015; 59:2682-2689.
2. Butcher GA. Antimalarial drugs and the mosquito transmission of Plasmodium. International Journal of Parasitology. 1997; 27(9):975-987.
3. Shanks GD. Treatment of falciparum malaria in the age of drug resistance. Journal of Post Graduate Medicine. 2006; 52(4):277-280.
4. Hastings I. How artemisinin-containing combination therapies slow the spread of antimalarial drug resistance. Trends in Parasitology. 2011; 27(2): 67-72.
5. White NJ. Antimalarial drug-resistance. Journal of Clinical Investigations. 2004; 113: 1084-1092.
6. White NJ, Pongtavornpinyo W. The de novo selection of drug-resistant malaria parasites. Proceedings-Biological Sciences. 2003; 270(1514): 545-554.
7. Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR. Epidemiology of drug-resistant malaria. The Lancet- Infectious Diseases. 2002; 2(4): 209-218.
8. Dutta P, Mahanta J. Response of Plasmodium Falciparum to chloroquine in Digboi area of Assam, India. The Journal of Communicable Diseases. 1996; 28(3): 212-214.
9. Campbell CC, Chin W, Collins WE, Teutsch SM, Moss DM. Chloroquine-resistant Plasmodium falciparum from East Africa: cultivation and drug sensitivity of the Tanzanian I/CDC strain from an American tourist. Lancet. 1979; 2(8153):1151-1154.
10. Peterson DS, Walliker D, Wellems TE. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proceedings of National Academy of Science of USA. 1988; 85(23): 9114-9118.
11. Kuile FO, Luxemburger C, Nosten F, Thwai KL, Chongsuphajaisiddhi T, White NJ. Predictors of Mefloquine treatment failure: A prospective study of 1590 patients with uncomplicated falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1995; 89(6): 660-664.
12. McKeage K, Scott L. Atovaquone/Proguanil: A review of its use for the prophylaxis of Plasmodium falciparum malaria. Drugs. 2003; 63(6): 597-623.
13. Price RN, Nosten F, Luxemburger C, Kham A, Brockman A, Chongsuphajaisiddhi T, White NJ. Artesunate versus artemether in combination with mefloquine for the treatment of multidrug-resistant falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1995; 89(6): 523-527.
14. Price RN, Nosten F, Luxemburger C, van Vugt M, Phaipun L, Chongsuphajaisiddhi T, White NJ. Artesunate/Mefloquine treatment of multi-drug resistant falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1997; 91(5): 574-577.
15. Krishna S, Uhlemann AC, Haynes RK. Artemisinins: mechanisms of action and potential for resistance; Drug Resistance updates- reviews and commentaries in antimicrobial and anticancer chemotherapy. 2004; 7(4-5): 233–244.
16. Sullivan DJ. Theories on malarial pigment formation and quinolone action. International Journal of Parasitology. 2002; 32(13): 1645–1653.
17. Egan TJ, Combrinck JM, Egan J, Hearne GR, Marques HM, Ntenteni S, Sewell BT, Smith PJ, Taylor D, van Schalkwyk DA, Walden JC. Fate of haem iron in the malaria parasite Plasmodium falciparum. The Biochemical Journal. 2002; 365(Pt 2): 343–347.
18. Tayade NG, Nagarsenkar MS. Development and evaluation of artemether parenteral microemulsion. Indian Journal of Pharmaceutical Sciences. 2010; 72(5): 637-640.
19. Karbwang J, Na-Bangchang K, Congpuong K, Molunto P, Thanavibul A. Pharmacokinetics and bioavailability of oral and intramuscular Artemether. European Journal of Clinical Pharmacology. 1997; 52(4): 307-310.
20. Chimanuka B, Gabriels M, Detaevernier MR, Plaizier-Vercammen JA. Preparation of β-Artemether liposomes, their HPLC-UV evaluation and relevance for clearing recrudescent parasitemia in P. chabaudi malaria infected mice. Journal of Pharmaceutical and Biomedical Analysis. 2002; 28(1): 13-22.
21. Joshi M, Pathak S, Sharma S, Patravale V; Design and in vivo pharmacodynamics evaluation of nanostructured lipid carriers for parenteral delivery of Artemether: Nanoject; International Journal of Pharmaceutics. 2008; 364(1): 119-126.
22. Chiou WL, Riegelman S. Pharmaceutical applications of solid dispersion systems. Journal of Pharmaceutical Sciences. 1971; 60(9): 1281–1302.
Statistics
1997 Views | 1576 Downloads
How to Cite
Maqbool, M., A. Dar, S. Rasool, and M. Khan. “CURIOUS CASE OF DRUG RESISTANT MALARIA AND ARTEMISININ COMPOUNDS IN THE MODERN ERA”. Journal of Applied Pharmaceutical Sciences and Research, Vol. 2, no. 2, July 2019, pp. 1-4, doi:10.31069/japsr.v2i2.1.
Issue
Volume 2, Issue 2, 2019
Section
Review Articles

All the articles published in JAPSR are distributed under a creative commons license (CC BY-NC-SA 4.0)

Under this license, you are free to:

  • Share- copy and redistribute the material in any medium or format for any purpose, even commercially.
  • Adapt- remix, transform, and build upon the material for any purpose, even commercially.

The licensor cannot revoke these freedoms as long as you follow the license terms.

  • Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  • NonCommercial — You may not use the material for commercial purposes .
  • ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

Copyright policy

The journal allows the author(s) to hold the copyright of their work. That means the authors do not need to transfer the copyright of their work to the journal. However, the authors grant JAPSR a license to publish the article and identify itself as the original publisher.

Licensing policy

The journal allows the author(s) to hold the copyright of their work. That means the authors do not need to transfer the copyright of their work to the journal. However, the authors grant JAPSR a license to publish the article and identify itself as the original publisher.